Towards an optimum strategy in rheumatoid arthritis

The Lancet

Volume 379, Issue 9827, 5–11 May 2012, Pages 1682-1684

Click to open first page preview

JS Smolen et al.
New therapies for treatment of rheumatoid arthritis
Lancet
(2007)
RF van Vollenhoven et al.
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
Lancet
(2009)
P Emery et al.
Early rheumatoid arthritis: time to aim for remission
Ann Rheum Dis
(1995)
JS Smolen et al.
Treating rheumatoid arthritis to target: recommendations of an international task force
Ann Rheum Dis
(2010)
EW St Clair et al.
Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group: combination of infliximab and methotrexate therapy for early rheumatoid arthritis
Arthritis Rheum
(2004)
FC Breedveld et al.
The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Arthritis Rheum
(2006)

There are more references available in the full text version of this article.